Acquisition Proposal - Biogen has made an unsolicited, non-binding proposal to acquire Sage Therapeutics for $7.22 per share, representing a 30% premium over Sage's closing price of $5.55 on Friday [1] - Biogen currently owns a 10.2% stake in Sage Therapeutics [1] - Sage Therapeutics' board will review and evaluate the offer [1] Stock Performance - Sage Therapeutics' stock surged 46% in after-hours trading following the news, while Biogen's shares declined slightly [2] - Over the past year, Biogen's shares have declined 40%, and Sage Therapeutics' stock has dropped 79.1%, compared to a 15.9% decrease in the industry [2] Zurzuvae Collaboration - Sage Therapeutics and Biogen have a collaboration for the commercialization of Zurzuvae, approved for postpartum depression (PPD) in August 2023 [3] - The companies equally share profits and losses for Zurzuvae in the US, while Biogen records product sales in non-US markets (excluding Japan, Taiwan, and South Korea) and pays royalties to Sage [4] - Zurzuvae has not yet been approved in the EU [4] Zurzuvae Development Setback - The FDA issued a complete response letter for Zurzuvae's major depressive disorder (MDD) indication in August 2023, requesting additional clinical studies [5] - In October 2024, the companies decided not to pursue further development of Zurzuvae for MDD due to the need for more time and investment [6] - If Biogen acquires Sage Therapeutics, it will gain full ownership of Zurzuvae, which has been outperforming launch expectations [6] Pipeline Setbacks - Sage Therapeutics discontinued the development of dalzanemdor (SAGE-718) for all indications in November 2024 after mid-stage studies failed to meet primary endpoints [8] - Biogen terminated its rights under the collaboration agreement for SAGE-324 (BIIB124) in essential tremor (ET) after a phase II study failed in July 2024 [9] Zacks Rank & Biotech Stocks - Sage Therapeutics has a Zacks Rank 2 (Buy), while Biogen has a Zacks Rank 3 (Hold) [10] - Top-ranked biotech stocks include Puma Biotechnology (PBYI) and Castle Biosciences (CSTL), both with a Zacks Rank 1 (Strong Buy) [10] - Castle Biosciences' 2025 earnings estimates have narrowed from a loss of $1.88 per share to a loss of $1.84 per share, with shares surging 51.0% over the past year [11] - Puma Biotechnology's 2025 earnings per share estimates have increased from 52 cents to 55 cents, despite a 33.1% decline in shares over the past year [11] - Castle Biosciences has beaten earnings estimates in each of the trailing four quarters, with an average surprise of 172.72% [11] - Puma Biotechnology has beaten earnings estimates in three of the trailing four quarters, with an average surprise of 32.78% [12]

Company Performance - Shares of Biogen Inc have declined more than 50% in the past 18 months and are significantly below their 2015 peak of approximately $500 per share [5] Investment Focus - The Growth Stock Forum focuses on identifying great growth stocks with an emphasis on biotech and attractive risk/reward situations [2] - The forum features a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks expected to perform well in the current calendar year, and trading ideas targeting both short-term and medium-term moves [3]

Biogen Inc. (NASDAQ:BIIB) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay, thank you guys for joining us. Pleasure to have Biogen Management. Really looking forward to this conversation. Alisha, thank you for making time. I'll let you kick things off. Alisha Alaimo Thank you. I t ...

Biogen Inc. (NASDAQ:BIIB) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay, thank you guys for joining us. Pleasure to have Biogen Management. Really looking forward to this conversation. Alisha, thank you for making time. I'll let you kick things off. Alisha Alaimo Thank you. I t ...

Clinical Trial Results - Dapirolizumab pegol (DZP) met its primary endpoint, showing statistically and clinically significant improvement across all organ systems as measured by BICLA, with a 14.6% higher response rate (49.5%) compared to standard of care (SOC) alone (34.6%) [1][2] - Participants receiving DZP experienced 50% fewer severe disease flares compared to those on SOC alone [1] - At Week 24, DZP plus SOC showed a 7.9% higher BICLA response rate (46.6%) compared to SOC alone (38.3%), though the difference was not statistically significant [3] Secondary Endpoints and Clinical Improvements - 17.1% more participants receiving DZP reduced their corticosteroid dose from >7.5 mg/day to ≤7.5 mg/day at Week 48 (72.4% vs. 52.9%) [4] - DZP plus SOC showed an 18.8% higher SRI-4 response rate at Week 48 (60.1% vs. 41.1%) [4] - A 1.8-fold greater decrease in SLEDAI-2K was observed in the DZP group compared to SOC alone at Week 48 (-6.1 vs. -4.2) [4] - 20.9% more participants in the DZP group achieved Lupus Low Disease Activity State (LLDAS) at Week 48 (40.9% vs. 19.6%) [4] Safety Profile - The safety profile of DZP was generally favorable, with 82.6% of participants experiencing treatment-emergent adverse events (TEAEs) compared to 75.0% in the SOC group [6] - Serious TEAEs were reported in 9.9% of participants receiving DZP plus SOC compared to 14.8% in the SOC group [6] - Opportunistic infections were reported in 2.8% of participants receiving DZP plus SOC compared to 0.9% in the SOC group [6] Disease Background - Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems, primarily in women, with 90% of cases occurring in women aged 15-55 [9] - SLE is associated with a higher risk of death from infections and cardiovascular disease, and pregnancy in women with SLE carries higher maternal and fetal risks [9] Drug Mechanism and Development - Dapirolizumab pegol is a novel Fc-free anti-CD40L drug candidate that inhibits CD40L signaling, reducing B cell activation and autoantibody production [10] - The drug is currently in Phase 3 clinical development for SLE under a collaboration between UCB and Biogen [10] Company Information - UCB is a global biopharmaceutical company focused on severe diseases of the immune system and central nervous system, listed on Euronext Brussels [11] - Biogen is a leading biotechnology company pioneering innovative science to deliver new medicines, founded in 1978 [12]

Needham downgraded Biogen Inc BIIB, citing limited catalysts for the company over the next year.Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue.Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million.Although investors are aware of this, market ...

Biogen Inc.’s (BIIB) Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending marketing approval for Leqembi (lecanemab) for early Alzheimer’s disease.The CHMP recommended marketing approval for Leqembi as a treatment of adult patients with early Alzheimer’s disease who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology in Europe.A final deci ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank put ...

Core Viewpoint - The article emphasizes the importance of value investing and highlights Biogen (BIIB) as a strong value stock based on various financial metrics [2][3][7] Financial Metrics - Biogen has a Zacks Rank of 2 (Buy) and an A for Value, indicating it is among the best value stocks currently available [3] - The company's Price-to-Book (P/B) ratio is 1.55, significantly lower than the industry average of 3.91, suggesting it is undervalued [4] - Biogen's Price-to-Sales (P/S) ratio stands at 2.63, compared to the industry's average of 6.73, further indicating its undervaluation [5] - The Price-to-Cash Flow (P/CF) ratio for Biogen is 10.23, which is attractive relative to the industry's average of 15.58 [6] Investment Outlook - The combination of Biogen's favorable financial metrics and strong earnings outlook positions it as one of the market's strongest value stocks [7]

Investment Group Overview - The investment group Haggerston BioHealth caters to both novice and experienced biotech investors, providing catalysts, buy/sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [2] - The group offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors, alongside access to investment bank-grade financial models and research [1] - Edmund Ingham, a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, leads the group and has compiled detailed reports on over 1,000 companies [2] Services and Expertise - The group provides detailed forecasts and sales data for all major pharmaceutical companies, along with integrated financial statements and discounted cash flow analysis [2] - Members can invest alongside a model portfolio or access high-quality financial models and research tailored to the biotech and healthcare sectors [1] - The group's focus on catalysts and market analysis helps investors identify potential opportunities and risks in the biotech and healthcare industries [2]